Kallikrein Inhibitor - Pipeline Insight, 2024

Kallikrein Inhibitor - Pipeline Insight, 2024

DelveInsight’s, “Kallikrein Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Kallikrein Inhibitor - Pipeline Insights, 2021 Understanding

Kallikrein Inhibitor - Pipeline Insights, 2021: Overview

Plasma prekallikrein is the liver-derived precursor of the trypsin-like serine protease plasma kallikrein, and circulates in plasma bound to high molecular weight kininogen. Plasma prekallikrein is activated to plasma kallikrein by activated factor XII or prolylcarboxypeptidase. Plasma kallikrein regulates the activity of multiple proteolytic cascades in the cardiovascular system such as the intrinsic pathway of coagulation, the kallikrein-kinin system, the fibrinolytic system, the renin-angiotensin system, and the complement pathways. As such, plasma kallikrein plays a central role in the pathogenesis of thrombosis, inflammation, and blood pressure regulation. Under physiological conditions, plasma kallikrein serves as a cardioprotective enzyme. However, its increased plasma concentration or hyperactivity perpetuates cardiovascular disease (CVD).

""Kallikrein Inhibitor - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Kallikrein Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Kallikrein Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kallikrein Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Kallikrein Inhibitor - Pipeline Insights, 2021 R&D. The therapies under development are focused on novel approaches to treat/improve Kallikrein Inhibitor - Pipeline Insights, 2021.

Kallikrein Inhibitor - Pipeline Insights, 2021 Emerging Drugs Chapters

This segment of the Kallikrein Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Kallikrein Inhibitor - Pipeline Insights, 2021 Emerging Drugs

• THR-149: Oxurion

THR-149 is a plasma kallikrein (PKal) inhibitor for treatment of DME. Through the inhibition of the plasma kallikrein-kinin (PKaI-kinin) system, THR-149 prevents the induction of retinal vascular permeability, inflammation and angiogenesis. Literature data show that patients with DME have elevated levels of plasma kallikrein and that the vitreous level of plasma kallikrein varies less compared to VEGF, making it a potentially more effective target for treating DME. Oxurion has reported positive topline phase 1 results for the clinical study evaluating THR-149 for the treatment of DME. It is currently in Phase II stage of development.

• Donidalorsen: Ionis Pharmaceuticals

Donidalorsen, formerly known as IONIS-PKK-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of prekallikrein, or PKK, to treat patients with hereditary angioedema, or HAE. PKK plays an important role in the activation of inflammatory mediators associated with acute attacks of HAE. HAE is a rare genetic disease characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. However, current prophylactic treatment approaches are very limited and have major tolerability issues due to challenging administration requirements leaving patients with few therapeutic options. It is currently in Phase II stage of development.

Further product details are provided in the report……..

Kallikrein Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment

This segment of the report provides insights about the different Kallikrein Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Kallikrein Inhibitor - Pipeline Insights, 2021

There are approx. 13+ key companies which are developing the therapies for Kallikrein Inhibitor - Pipeline Insights, 2021. The companies which have their Kallikrein Inhibitor - Pipeline Insights, 2021 drug candidates in the most advanced stage, i.e. Phase II include, Oxurion.

• Phases

DelveInsight’s report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Kallikrein Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kallikrein Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kallikrein Inhibitor - Pipeline Insights, 2021 drugs.

Kallikrein Inhibitor - Pipeline Insights, 2021 Report Insights

• Kallikrein Inhibitor - Pipeline Insights, 2021 Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Kallikrein Inhibitor - Pipeline Insights, 2021 Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Kallikrein Inhibitor - Pipeline Insights, 2021 drugs?
• How many Kallikrein Inhibitor - Pipeline Insights, 2021 drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kallikrein Inhibitor - Pipeline Insights, 2021?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Kallikrein Inhibitor - Pipeline Insights, 2021 therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Kallikrein Inhibitor - Pipeline Insights, 2021 and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Oxurion
• Intellia Therapeutics
• Ionis Pharmaceuticals
• KalVista Pharmaceuticals
• Astria Therapeutics

Key Products

• THR-149
• NTLA2002
• KVD-824
• Donidalorsen
• JNJ-78278343
• STAR-0215